New Treatment Shows Promise for Mesothelioma

In two patients who had exhausted all other possible treatment options, the newest cancer treatment that is being considered for mesothelioma was able to stop the growth of the aggressive tumors.
The two patients had tumors that continued to grow despite treatment with cancer drugs. One patient was an 18-year-old who had a tumor on his femur (malignant fibroud histiocytoma (MFH)). From the tumor on his leg bone, the cancer spread throughout his body to his lungs. This occurred after physicians chose the drastic action of amputating his leg and replacing it with metal implants. Desmoplastic small round cell tumor (DSRCT) was the rare cancer suffered by the other patient in the study. Like the first patient, even after surgery and chemotherapy, the cancer had not subsided.

Following an eight-week course of the NeoPlas regimen, the patients’ scans showed that their cancers had stopped growing and some of the tumors were seen to shrink. The treatment was also well tolerated by both of the patients, who were able to conduct day-to-day activities.

According to Dr. Stephen B. Cantrell, the NeoPlas Innovation Director of Research, “These are early results and not statistically valid yet. Still, the sarcomas as a group are so aggressive and uniformly fatal that being able to stop their growth and spread is very exciting. It’s a major victory for these individuals, and it mirrors the success we’re seeing in the great majority of patients so far.”

Those who suffer from kidney cancer, pancreatic cancer, melanoma, mesothelioma, and colon cancer and who pass the screening process would qualify for future study of the NeoPlas regimen.

NeoPlas combines a cholesterol-lowering drug, lovastatin, and interferon. The timing used to alternate these drugs appears to win battles in the war on the most aggressive forms of cancer for some patients.

Side effects commonly seen with chemotherapy such as nausea, hair loss, and immune system suppression did not occur in patients on the NeoPlas Innovation treatment regimen. Most in the outpatient treatment only experienced some fatigue.